Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

Featured in Pancreas

Featured in the March 2017 issue of Pancreas are the NANETS 2016 symposium 

In memoriam Dirk J. Kwekkeboom (1958 - 2017)

Dirk J. KwekkeboomDirk J. Kwekkeboom, MD, widely regarded as one of Europe’s foremost experts on peptide receptor radiotherapy (PRRT), passed away March 8, 2017, at the age of 58. 

FDA approves Xermelo for carcinoid syndrome diarrhea

On February 28th, 2017, The U.S. Food and Drug Administration (FDA) approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. “Today’s approval will provide patients whose carcinoid syndrome diarrhea is not adequately controlled with another treatment option,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

Jan 2017 NETwork Connection- Clinical Trials

Clinical Trials In the News:

On January 12, that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”). 

2017 ASCO GI Preview

ASCO GI Header

The 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium will run from Thursday, January 19 through Saturday, January 21 in San Francisco, California. The symposium will feature two sessions on neuroendocrine tumors (NETs), as well as poster presentations and an oral abstract presentation on NET research and therapy.

FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

On June 1, 2016, the U.S. Food and Drug Administration (FDA) granted approval to Netspot, the first kit for the preparation of Gallium-68 dotatate positron emission tomography (68Ga-dotatate PET) imaging. Gallium-68 dotatate is a positron-emitting analogue of somatostatin, and the radioactive probe helps locate tumors in patients with somatostatin receptor-positive neuroendocrine tumors.

FDA grants a priority review of the new drug application for telotristat etiprate

On May 31, 2016, the U.S. Food and Drug Administration (FDA) granted a priority review of the new drug application for telotristat etiprate (Lexicon), and oral drug used to treat carcinoid syndrome. As the priority review status shortens the review process to 6 months from the standard 10 months, the FDA will decide whether to approve telotristat etiprate for commercial use by November 30, 2016.

Pancreas Journal Publishes Abstracts from the 2015 NANETS Annual Symposium

The 2015 NANETS Annual Symposium Abstracts are now in print in Pancreas 2016 Volume 45 #3, March issue. The abstracts can be viewed at no charge by clicking here to the Journal's website.

FDA approves new indication for Novartis drug Afinitor® for progressive, non-functional GI and lung neuroendocrine tumors (NETs)

Novartis

On February 26, 2016, the U.S. Food and Drug Administration (FDA) approved everolimus (Afinitor®, Novartis) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority review designation providing a shortened review period for drugs that treat serious conditions and offer a significant improvement in safety or effectiveness.

2015 YI and NCIS Scholarship Recipients

Developing the next generation of clinicians and researchers in the field of neuroendocrine tumors (NETs) is an important objective of NANETS. This grant offers a platform to highlight and financially support the NET research conducted by junior investigators in the field.

Pages